


PATENT
Docket No. 399632002920

CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:
Assistant Commissioner for Patents, Washington, D.C. 20231, on July 31, 2002.


Jose Luna

RECEIVED

AUG 08 2002

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

John SIDNEY et al.

Serial No.: 09/935,476

Filing Date: August 22, 2001

For: SUBUNIT VACCINES WITH A2
SUPERMOTIFS

Examiner: To be assigned

Group Art Unit: 1644

**INFORMATION DISCLOSURE
STATEMENT UNDER 37 C.F.R. § 1.97**

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Pursuant to 37 C.F.R. § 1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents, numbers 10-13, 15-17, 20, 29, 32, 35, 37, 40, 43, 48-50, 53-54, 56, 58, 66, 69, 73, 75, 81, 83-84, 87, 89-92, and 94-95, listed on the attached Form PTO-1449. Copies of all other documents were previously submitted in an Information Disclosure Statement and/or Office Action, directed to the related application Serial Number 09/346,105, filed June 30, 1999, and, accordingly, copies are not included herewith. This protocol conforms with 37 C.F.R. § 1.98(d) and M.P.E.P. 609(A)(2). The Examiner is requested to make these documents of record in the application.

This application is a continuation-in-part of U.S. Application Serial No. 09/346,105 filed June 30, 1999. This application is also related to U.S. Application Serial No. 60/264,969 filed January 29, 2001.

This Information Disclosure Statement is submitted:

- ☐ With the application; accordingly, no fee or separate requirements are required.
- ☒ Within three months of the application filing date or before mailing of a first Office Action on the merits; accordingly, no fee or separate requirements are required.
- ☐ After receipt of a first Office Action on the merits but before mailing of a final Office Action or Notice of Allowance.
 - ☐ A fee is required. A check in the amount of * is enclosed.
 - ☐ A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided below; accordingly, no fee is believed to be due.
- ☐ After mailing of a final Office Action or Notice of Allowance, but before payment of the issue fee.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided below and a check in the amount of * is enclosed.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided below and a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.


Applicants would appreciate the Examiner initialing and returning the Form PTO-1449, indicating that the information has been considered and made of record herein.

The information contained in this Information Disclosure Statement under 37 C.F.R. § 1.97 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines that an extension and/or other relief is required, applicant petitions for any required relief including extensions of time and authorizes the Assistant Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing 399632002920. However, the Assistant Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Dated: July 30, 2002

Respectfully submitted,

By: 

Irina E. Britva
Registration No. 50,498

Morrison & Foerster LLP
3811 Valley Centre Drive
Suite 500
San Diego, California 92130-2332
Telephone: (858) 720-5175
Facsimile: (858) 720-5125

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>				Docket Number 399632002920		Application Number 09/935,476	
				Applicant <div style="text-align: center;">John SIDNEY et al.</div>			
				Filing Date August 22, 2001		Group Art Unit 1644	
				Mailing Date July <u>31</u> , 2002			

RECEIVED
 AUG 08 2002
 TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS							
Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date if Appropriate
	1.	04/1993	5,200,320	Sette et al.	435	7.24	
	2.	08/1994	5,342,774	Boon et al.	435	240.2	
	3.	04/1995	5,405,940	Boon et al.	530	328	

FOREIGN PATENT DOCUMENTS							
Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES NO
	4.	02/1992	WO 92/02543	WIPO			
	5.	11/1992	WO 92/21033	WIPO			
	6.	03/1994	WO 94/05304	WIPO			
	7.	07/1994	WO 94/11738	WIPO			
	8.	09/1994	WO 94/20127	WIPO			
	9.	09/1995	WO 95/25122	WIPO			
	10.	09/1997	WO97/34621	WIPO			

OTHER DOCUMENTS			(including author, title, Date, Pertinent Pages, Etc.)
Examiner Initials	Ref. No.	Title	
	11. ✓	Ahlers et al. "Enhanced Immunogenicity of HIV-1 Vaccine Construct by Modification of the Native Peptide Sequence" Proc Natl Acad Sci USA (1997) 94:10856-10861	
	12. ✓	Bakker et al. "Analogues of CTL Epitopes with Improved MHC Class-I Binding Capacity Elicit Anti-Melanoma CTL Recognizing the Wide-Type Epitope" Int. J. Cancer (1997) 70:302-309	
	13. ✓	Barouch et al. "HLA-A2 Subtypes Are Functionally Distinct in Peptide Binding and Presentation" J Exp Med. (1995) 182:1847-1856	
	14. ✓	Battegay et al. "Patients with Chronic Hepatitis C Have Circulating Cytotoxic T Cells Which Recognize Hepatitis C Virus-Encoded Peptides Binding to HLA-A2.1 Molecules" Journal of Virology (1995) 2462-2470	
	15. ✓	Bertoletti et al. "Molecular Features of the Hepatitis B Virus Nucleocapsid T-Cell Epitope 18-27: Interaction with HLA An T-Cell Receptor" Hepatology (1997) 26:1027-1034	

EXAMINER:	DATE CONSIDERED:
-----------	------------------

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449

Docket Number 399632002920

Application Number 02915476

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

(Use several sheets if necessary)

Applicant

John SIDNEY et al.

Filing Date August 22, 2001

Group Art Unit 1644

Mailing Date July 31, 2002

AUG 9 8 2002

TECH CENTER 1600/2900

16.	Bertoni et al. "Human Histocompatibility Leukocyte Antigen-Binding Supermotifs Predict Broadly Cross-Reactive Cytotoxic T Lymphocyte Responses in Patients with Acute Hepatitis" J Clin Invest (1997) 100:503-513
17.	Bertoni et al. "Human Class I Supertypes and CTL Repertoires Extend to Chimpanzees" J. Immunol. (1998) 161:4447-4455
18.	Bjorkman et al. "Structure of the Human Class I Histocompatibility Antigen HLA-A2" Nature (1987) 329:506
19.	Bruss. "A Short Linear Sequence in the Pre-S Domain of the Large Hepatitis B Virus Envelope Protein Required for Virion Formation" Journal of Virol. (1997) 71:9350-9357
20.	Buus et al. "Autologous Peptides Constitutively Occupy the Antigen Binding Site on Ia" Science (1988) 242:1045-1047
21.	Buus et al. "Autologous Peptides Constitutively Occupy the Antigen Binding Site on Ia" Science (1998) 242:1045-1047
22.	Carreno et al. "HLA-B37 and HLA-A2.1 Molecules Bind Largely Nonoverlapping Sets of Peptides" Proc. Natl. Acad. Sci. USA (1990) 87:3420-3424
23.	Celis et al. "Identification of Potential CTL Epitopes of Tumor-Associated Antigen MAGE-1 for Five Common HLA-A Alleles" Mol. Immunol. (1994) 31:1423-1430
24.	Celis et al. "Induction of Anti-Tumor Cytotoxic T Lymphocytes in Normal Humans Using Primary Cultures and Synthetic Peptide Epitopes" Proc. Natl. Acad. Sci. USA (1994) 91:2105-2109
25.	Cerny et al. "Induction In Vitro of a Primary Human Antiviral Cytotoxic T Cell Response" Eur. J. Immunol. (1995) 25:627-630
26.	Cotran, ed. (1989) Robbins Pathologic Basis of Disease, 4 th ed., W.B. Saunders Co., Philadelphia pp.296-299
27.	Cox et al. "Melanoma-Specific Human Cytotoxic T Cells Lines" Science (1994) 264:716-719
28.	De Bruijn et al. "Peptide Loading of Empty Major Histocompatibility Complex Molecules on RMA-S Cells Allows the Induction of Primary Cytotoxic T Lymphocyte Responses" Eur. J. Immun. (1991) 21:2963-2970
29.	Del Guercio et al. "Binding of a Peptide Antigen to Multiple HLA Alleles Allows Definition of an A2-Like Supertype" J. Immunol. (1995) 154:685-693
30.	DiBrino et al. "Endogenous Peptides Bound to HLA-A3 Possess A Specific Combination of Anchor Residues That Permit Identification of Potential Antigenic Peptides" Proc. Natl. Acad. Sci. USA (1993) 90:1508-1512
31.	Ding et al. "Cloning and Analysis of MAGE-1 Related Genes" Biochem. Biophys. Res. Commun. (1994) 202(1):549-555
32.	Doolan et al. "Degenerate Cytotoxic T-Cell Epitopes from <i>P. falciparum</i> Restricted by Multiple HLA-A and HLA-B Supertype Alleles" Immunity (1997) 7:97-112

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

(Use several sheets if necessary)

Docket Number 399632002920

Application Number 09/935,446

Applicant

John SIDNEY et al.

Filing Date August 22, 2001

Group Art Unit 1644

Mailing Date July 31, 2002

RECEIVED
AUG 08 2002
TECH CENTER 1600/2900

33.	Englehard et al. "Structure of Peptides Associated with MHC Class I Molecules" Curr. Opin. Immunol. (1994) 6:13-23
34.	Falk et al. "Allele-Specific Motifs Revealed by Sequencing of Self-Peptide Eluted from MHC Molecules" Nature (1991) 351:290-296
35.	Fleischhauer et al. "Multiple HLA-A Alleles Can Present an Immunodominant Peptide of the Human Melanoma Antigen Melan-A/MART-1 to a Peptide-Specific HLA-A*201+ Cytotoxic Cell Line" J Immunol (1996) 157:787-797
36.	Foon. "Biological Response Modifiers: The New Immunotherapy" (1989) 49:1621-1639
37.	Fruci et al. "Anchor Residue Motifs of HLA Class-I-Binding Peptides Analyzed by the Direct Binding of Synthetic Peptides to HLA Class I α Chains" Hum. Immunol. (1993) 38:187-192
38.	Fynan et al. "DNA Vaccines: Protective Immunizations by Parenteral, Mucosal, and Gene-Gun Inoculations" Proc. Natl. Acad. Sci. USA (1993) 90:11478-11482
39.	Gaugler et al. "Human Gene MAGE-3 Codes for an Antigen Recognized on a Melanoma by Autologous Cytolytic T Lymphocytes" J. Exp. Med. (1994) 179(3):921-930
40.	Gulukota et al. "Two Complimentary Methods for Predicting Peptides Binding Major Histocompatibility Complex Molecules" J. Mol. Biol. (1997) 267:125-1267
41.	Hayashi et al. "Molecular Cloning and Characterization of the Gene Encoding Mouse Melanoma Antigen by cDNA Library Transfection" J. Immunol. (1992) 149:1223-1229
42.	Henderson et al. "HLA-A2.1-Associated Peptides from a Mutant Cell Line: A Second Pathway of Antigen Presentation" Science (1992) 255:1264-1266
43.	Hunt et al. "Characterization of Peptides Bound to the Class I MHC Molecule HLA-A2.1 by Mass Spectrometry" Science (1992) 225: 1261-1263
44.	Hunt et al. "Characterization of Peptides Bound to the Class I MHC Molecule HLA-A2.1 by Mass Spectrometry" Science (1992) 255:1261-1263
45.	Jardetzky et al. "Identification of Self Peptides Bound to Purified HLS-B27" Nature (1991) 353:326-329
46.	Jiang et al. "Role of CD8* T Cells in Murine Experimental Allergic Encephalomyelitis" Science (1992) 256:1213-1215
47.	Kannagi et al. "Target Epitope in the Tax Protein of Human T Cell Leukemia Virus Type I Recognized By Class I Major Histocompatibility Complex-Restricted Cytotoxic T Cells" J. of Virol. (1992) 66(5):2928-2933
48.	Kast et al. "Role of HLA-A Motifs in Identification of Potential CTL Epitopes in Human Papillomavirus Type 16 E6 and E7 Proteins" J. Immunol. (1994) 152:3904-3912
49.	Kawashima. "The Multi-Epitope Approach for Immunotherapy for Cancer: Identification of Several CTL Epitopes from Various Tumor-Associated Antigens Expressed on Solid Epithelial Tumors" Hum Immunol (1998) 59:1-14

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449		Docket Number 399632002920	Application Number 09/935,476
INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>		Applicant John SIDNEY et al.	
		Filing Date August 22, 2001	Group Art Unit 1644
		Mailing Date July 31, 2002	

50.	Khanna et al. "Identification of Cytotoxic T-Cell Epitopes Within Epstein-Barr Virus (EBV) Oncogene Latent Membrane Protein 1 (LMP1): Evidence for HLA A2 Supertype-Restricted Immune Recognition of EBV-Infected Cells by LMP1-Specific Cytotoxic T Lymphocytes" Eur J Immunol (1998) 28:451-458
51.	Knuth et al. "Cellular and Humoral Immune Responses Against Cancer: Implications for Cancer Vaccines" Curr. Opinion Immunol.(1991) 3:659-664
52.	Koh et al. "Less Mortality But More Relapses in Experimental Allergic Encephalomyelitis in CDB-/- Mice" Science (1992) 256:1210-1213
53.	Kondo et al. "Prominent Roles of Secondary Anchor Residues in Peptide Binding to HLA-A24 Human Class I Molecules" J. Immunol. (1995) 155:4307-4312
54.	Kondo et al. "Two Distinct HLA-A*0101-Specific Submotifs Illustrate Alternative Peptide Binding Modes" Immunogenetics (1997) 45:249-258
55.	Krieger et al. "Single Amino Acid Changes in DR and Antigen Define Residues Critical for Peptide-MHC Binding and T Cell Recognition" J. Immunol. (1991) 146:2331-2340
56.	Livingston et al. "Immunization with the HBV Core 18-27 Epitope Elicits CTL Responses in Humans Expressing Different HLA-A2 Supertype Molecules" Hum Immunol. (1999) 60:1013-1017
57.	Maryanski et al. "Competitor Analogs for Defined T Cell Antigens: Peptides Incorporating a Putative Binding Motif and Polyproline or Polyglycine Spacers" Cell (1990) 60:63-72
58.	Milik et al. "Application of an Artificial Neural Network to Predict Specific Class I MHC Binding Peptide Sequences" Nature (Biotech) (1998) 16:753-756
59.	Miller et al. "Suppressor T Cells Generated by Oral Tolerization to Myelin Basic Protein to Suppress Both In Vitro and In Vivo Immune Responses by the Release of Transforming Growth Factor β After Antigen Specific Triggering" Proc. Natl. Acad. Sci. USA (1992) 89:421-425
60.	Morrison et al. "Identification of the Nonamer Peptide from Influenza A Matrix Protein and the Role of Pockets of HLA-A2 in its Recognition by Cytotoxic T Lymphocytes" Eur. J. Immunol. (1992) 2:903-907
61.	Oaks et al. "Molecular Cytogenetic Mapping of the Human Melanoma Antigen (MAGE) Gene Family to Chromosome Region Xq27-qtr: Implications for MAGE Immunotherapy" Cancer Res. (1994) 54:1627-1629
62.	Ochoa-Garay et al. "The Ability of Peptides to Induce Cytotoxic T Cells in Vitro Does Not Strongly Correlate with their Affinity for the H-SLD Molecule: Implications for Vaccine Design and Immunotherapy" Molec. Immunol. (1997) 34: 273-281
63.	Pamer et al. "Precise Prediction of a Dominant Class I MHC-Restricted Epitope of Listeria Monocytogenes" Nature (1991) 353:852-855
64.	Parker et al. "Peptide Binding to HLA-A2 and HLA-B27 Isolated from Escherichia coli" J. Biol. Chem. (1992) 267(8):5451-5459

EXAMINER:	DATE CONSIDERED:
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.	

Form PTO-1449

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

(Use several sheets if necessary)

Docket Number 399632002920

Application Number 09/935,476

Applicant

John SIDNEY et al.

Filing Date August 22, 2001

Group Art Unit 1644

Mailing Date July 31, 2002

RECEIVED
AUG 08 2002
TECH CENTER 1600/2900

65.	Parker et al. "Sequence Motifs Important for Peptide Binding to the Human MHC Class I Molecule, HLA-A2" J. Immunol. (1992) 149:3580-3587
66.	Parkhurst. "Improved Induction of Melanoma-Reactive CTL with Peptides from the Melanoma Antigen gp100 Modified at HLA-A*0201-Binding Peptides" J Immunol. (1996) 157:2539-2548
67.	Paul, ed. (1989) <u>Fundamental Immunology</u> , 2 nd ed., Raven Press, NY pp.473-487
68.	Paul, ed. (1993) <u>Fundamental Immunology</u> , 3 rd ed., Raven Press, NY pp.976-978
69.	Pogue et al. "Amino-Terminal Alteration of the HLA-A*0201-Restricted Human Immunodeficiency Virus Pol Peptide Increases Complex Stability and In Vitro Immunogenicity" Proc Natl Acad Sci USA (1995) 92:8166-8170
70.	Preisler-Adams et al. "Complete Nucleotide Sequence of a Hepatitis B Virus, Subtype ADW2, and Identification of Three Types of C Open Reading Frames" Nucleic Acids Res. (1993) 21:2258
71.	Rammensee et al. "Peptides Naturally Presented by MHC Class I Molecules" (1993) Annu. Rev. Immunol. 11:213-44
72.	Rammensee et al. "MHC Ligands and Peptide Motifs: First Listing" Immunogenet. (1995) 41:178-228
73.	Rivoltini et al. "Binding and Presentation of Peptides Derived from Melanoma Antigens MART-1 and Glycoprotein-100 by HLA-A2 Subtypes: Implications for Peptide-Based Immunotherapy" J Immunol (1996) 156:3882-3891
74.	Romero et al. "H-2Kd Restricted Antigenic Peptides Share a Simple Binding Motif" (1991) 174:603-612
75.	Rosenberg et al. "Immunologic and Therapeutic Evaluation of a Synthetic Peptide Vaccine for the Treatment of Patients with Metastatic Melanoma" Nature (Med) (1998) 4:321-327
76.	Rotzschke et al. "Characterization of Naturally Occurring Minor Histocompatibility Peptides Including H-4 and H-Y" Science (1990) 249:283-287
77.	Rotzschke et al. "Isolation and Analysis of Naturally Processed Viral Peptides As Recognized by Cytotoxic T Cells" Nature (1990) 348:252-254
78.	Rotzschke et al. "Naturally Occurring Peptide Antigens Derived from the MHC Class I Restricted Processing Pathway" Immunology Today (1991) 12(12):447-455
79.	Rotzschke et al. "Peptide Motifs of Closely Related HLA Class I Molecules Encompass Substantial Differences" Eur. J. Immunol. (1992) 22:2453-2456
80.	Rudinger. "Characteristics of the Amino Acids As Components of a Peptide Hormone Sequence" in <u>Peptide Hormones</u> Parsons, ed. (1976) J.A. University Park Press, pp.1-7
81.	Ruppert et al. "Prominent Role of Secondary Anchor Residues in Peptide Binding to HLA-A2.1 Molecules" Cell (1993) 74:929-937
82.	Sarobe et al. "Induction of Antibodies Against a Peptide Hapten Does Not Require Covalent Linkage Between the Hapten and a Class II Presentable T Helper Peptide" Eur. J. Immunol. (1991) 21:1555-

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

(Use several sheets if necessary)

Docket Number 399632002920

Application Number 09/935,476

Applicant

John SIDNEY et al.

Filing Date August 22, 2001

Group Art Unit 1644

Mailing Date July 31, 2002

RECEIVED
AUG 08 2002
TECH CENTER 1600/2900

	1558
83.	Sarobe et al. "Enhanced In Vitro Potency and In Vivo Immunogenicity of a CTL Epitope from Hepatitis C Virus Core Protein Following Amino Acid Replacement at Secondary HLA-A2.1 Binding Positions" J Clin Invest (1998) 102:1239-1248
84.	Schaeffer et al. "Relative Contribution of "Determinant Selection" and "Holes in the T-Cell Repertoire" to T-Cell Responses" Proc. Nat'l. Acad. Sci. USA (1989) 86:4649-4653
85.	Sette et al. "Prediction of Major Histocompatibility Complex Binding Regions by Sequence Pattern Analysis" Proc. Nat'l. Acad. Sci. USA (1989) 86:3296-3300
86.	Sette et al. "Random Association Between the Peptide Repertoire of A2.1 Class I and Several Different DR Class II Molecules" J. of Immunol. (1991) 147:3893-3900
87.	Sette et al. "The Relationship Between Class I Binding Affinity and Immunogenicity of Potential Cytotoxic T Cell Epitopes" J. Immunol. (1994) 153:5586-5592
88.	Shimojo et al. "Specificity of Peptide Binding by the HLA-A2.1 Molecule" J. of Immunol. (1989) 143(9):2939-2947
89.	Sidney et al. "Definition of an HLA-A3-Like Supermotif Demonstrates the Overlapping Peptide Binding Repertoires of Common HLA Molecules" Human Immunol. (1996) 45:79-93
90.	Sidney et al. "Practical, Biochemical and Evolutionary Implications of the Discovery of HLA Class I Supermotifs" Immunol Today (1996) 17:261-266
91.	Sidney et al. "Specificity and Degeneracy in Peptide Binding to HLA-B7-Like Class I Molecules" J Immunol (1996) 157:3480-3490
92.	Sidney et al. "The HLA-A*0207 Peptide Binding Repertoire is Limited to a Subset of the A*0201 Repertoire" Hum. Immunol. (1997) 58:12-20
93.	Slingluff et al. "Recognition of Human Melanoma Cells by HLA-A2.1-Restricted Cytotoxic T Lymphocytes is Mediated by at Least Six Shared Peptide Epitopes" J. Immunol. (1993) 150:2955-2960
94.	Southwood et al. "Several Common HLA-DR Types Share Largely Overlapping Peptide Binding Repertoires" J Immunol. (1998) 160:3363-3373
95.	Sudo et al. "Differences in MHC Class I Self Peptide Repertoires Among HLA-A2 Subtypes" J. Immunol. (1995) 155:4749-4756
96.	Storkus et al. "Identification of Human Melanoma Peptides Recognized by Class I Restricted Tumor Infiltrating T Lymphocytes" J. Immunol. (1993) 151:3719-3727
97.	Traversari et al. "A Nonapeptide Encoded by Human GeneMAGE-1 Is Recognized On HLA-A1 By Cytolytic T Lymphocytes Directed Against Tumor Antigen MZ2-E" J. Exp. Med. (1992) 176:1453-1457
98.	Urban et al. "Autoimmune T Cells: Immune Recognition of Normal and Variant Peptide Epitopes and Peptide Based Therapy" Cell (1989) 59:247-255

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

(Use several sheets if necessary)

Docket Number 399632002920

Application Number 09/935,476

Applicant

John SIDNEY et al.

Filing Date August 22, 2001

Group Art Unit 1644

Mailing Date July 31, 2002

- | | |
|------|--|
| 99. | Van der Bruggen et al. "A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma" Science (1991) 254:1643-1647 |
| 100. | Viret et al. "Recognition of Shared Melanoma Antigen by HLA-A2 Restricted Cytolytic T Cell Clones Derived from Human Tumor-Infiltrating Lymphocytes" Eur. J. Immunol (1993) 23:141-146 |
| 101. | Wei et al. "HLA-A2 Molecules in an Antigen-Processing Mutant Cell Contain Signal Sequence-Derived Peptides" Nature (1992) 356:443-446 |
| 102. | Weynants et al. "Expression of MAGE Genes by Non-Small-Cell Lung Carcinomas" Int. J. Cancer (1994) 56: 826-829 |
| 103. | Wraith et al. "Antigen Recognition in Autoimmune Encephalomyelitis and the Potential for Peptide-Mediated Immunotherapy" Cell (1989) 59:247-255 |
| 104. | Zakut et al. "Differential Expression of MAGE-1, -2 and -3 Messenger RNA in Transformed and Normal Human Cell Lines" Cancer Res. (1993) 53:5-8 |

RECEIVED
AUG 08 2002
TECH CENTER 1600/2900

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.